# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Pancreatic cancer 2

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 73 results.
Screening for PDAC in BRCA1/2 Patients
Status: Recruiting
Last Changed: Mar 25, 2019
First Received: Jun 23, 2015
Disease(s): Pancreatic Cancer
Intervention(s): prophylactic endoscopic ultrasound
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial
Status: Recruiting
Last Changed: Mar 21, 2019
First Received: Jun 12, 2018
Disease(s): Pancreatic Cancer
Intervention(s): Niraparib Treatment
Locations: University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States
University of Kansas Cancer Center - West, Kansas City, Kansas, United States
University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States
The University of Kansas Cancer Center, Westwood, Kansas, United States
University of Kansas Cancer Center - North, Kansas City, Missouri, United States
... and 2 other locations.
Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis
Status: Recruiting
Last Changed: Jan 25, 2019
First Received: May 15, 2018
Disease(s): Pancreatic Cancer
Intervention(s): Liquid Biopsy
Locations: St Vincent university Hospital, Dublin, Ireland
Policlinico Universitario Agostino Gemelli, Roma, Italy
AOU Sant'Andrea - UOC Chirurgia Generale, Roma, Italy
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
Status: Recruiting
Last Changed: Aug 29, 2018
First Received: May 04, 2017
Disease(s): Pancreatic Cancer
Intervention(s): RUCAPARIB
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI
Status: Recruiting
Last Changed: Jul 19, 2019
First Received: Oct 03, 2018
Disease(s): Metastatic Pancreatic Cancer
Intervention(s): Irinotecan Liposomal Injection, 5-FU/LV, Nab-Paclitaxel, Gemcitabine
Locations: Clinique privée de l'Europe, Amiens, France
CHU Hôtel Dieu, Angers, France
Hôpital privé, Antony, France
CH, Auxerre, France
CH de la Côte Basque, Bayonne, France
... and 32 other locations.
Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients
Status: Not yet recruiting
Last Changed: Sep 11, 2017
First Received: Sep 11, 2017
Disease(s): Cancer of Pancreas
Intervention(s): Nab-paclitaxel plus Gemcitabine, Gemcitabine monotherapy, S-1 monotherapy
Locations: Chinese PLA General Hospital, Beijing, Beijing, China
Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers
Status: Recruiting
Last Changed: Aug 19, 2019
First Received: Feb 17, 2016
Disease(s): Healthy Subject, Pancreatic Carcinoma
Intervention(s): Computed Tomography, Laboratory Biomarker Analysis, PET/MRI scan, [18F]FP-R01-MG-F2
Locations: Stanford University, School of Medicine, Palo Alto, California, United States
A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
Status: Recruiting
Last Changed: Aug 07, 2019
First Received: Nov 06, 2017
Disease(s): Pancreatic Cancer, Pancreas Adenocarcinoma, Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Intervention(s): Pembrolizumab, paricalcitol, placebo
Locations: HonorHealth Research Institute, Scottsdale, Arizona, United States
City of Hope National Medical Center, Duarte, California, United States
The University of Kansas Cancer Center, Westwood, Kansas, United States
Atlantic Medical Group-Oncology Morristown Medical Center, Morristown, New Jersey, United States
Baylor University Medical Center Charles A. Sammons Cancer Center, Dallas, Texas, United States
... and 2 other locations.
A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
Status: Recruiting
Last Changed: Mar 12, 2019
First Received: Aug 30, 2012
Disease(s): Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Intervention(s): siG12D-LODER, Gemcitabine+nab-Paclitaxel
Locations: Hackensack Meridian Health, Hackensack, New Jersey, United States
The Mount Sinai Hospital, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
MD Anderson Cancer Center, Houston, Texas, United States
Rambam Medical Center, Haifa, Israel
... and 4 other locations.
CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
Status: Recruiting
Last Changed: Feb 22, 2019
First Received: Feb 22, 2019
Disease(s): Pancreatic Ductal Adenocarcinoma
Intervention(s): 64Cu-DOTA-ECLIi, CTI/Siemens Biography 40 PET/CT
Locations: Washington University School of Medicine, Saint Louis, Missouri, United States